Beam Therapeutics Inc. (NASDAQ: BEAM) stock fell -3.27% on Wednesday to $33.38 against a previous-day closing price of $34.51. With 0.69 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.99 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $34.53 whereas the lowest price it dropped to was $33.02. The 52-week range on BEAM shows that it touched its highest point at $73.27 and its lowest point at $28.04 during that stretch. It currently has a 1-year price target of $67.00.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BEAM was down-trending over the past week, with a drop of -4.52%, but this was up by 9.66% over a month. Three-month performance dropped to -17.54% while six-month performance fell -26.49%. The stock lost -4.60% in the past year, while it has lost -14.65% so far this year. A look at the trailing 12-month EPS for BEAM yields -4.46 with Next year EPS estimates of -5.93. For the next quarter, that number is -1.43. This implies an EPS growth rate of 28.40% for this year and -5.30% for next year.
Float and Shares Shorts:
At present, 72.27 million BEAM shares are outstanding with a float of 69.16 million shares on hand for trading. On Apr 27, 2023, short shares totaled 12.73 million, which was 17.05% higher than short shares on Mar 30, 2023. In addition to Mr. John M. Evans M.B.A. as the firm’s CEO & Director, Dr. Giuseppe Ciaramella Ph.D. serves as its Pres.
Through their ownership of 85.44% of BEAM’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 43.26% of BEAM, in contrast to 32.98% held by mutual funds. Shares owned by individuals account for 18.73%. As the largest shareholder in BEAM with 11.84% of the stake, ARK Investment Management LLC holds 8,573,429 shares worth 8,573,429. A second-largest stockholder of BEAM, The Vanguard Group, Inc., holds 6,217,361 shares, controlling over 8.59% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in BEAM, holding 4,422,926 shares or 6.11% stake. With a 8.49% stake in BEAM, the ARK Innovation ETF is the largest stakeholder. A total of 6,143,656 shares are owned by the mutual fund manager. The ARK Genomic Revolution ETF, which owns about 2.89% of BEAM stock, is the second-largest Mutual Fund holder. It holds 2,095,394 shares valued at 64.35 million. Vanguard Total Stock Market ETF holds 2.88% of the stake in BEAM, owning 2,083,792 shares worth 63.99 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, BEAM reported revenue of $16.65M and operating income of -$81.97M. The EBITDA in the recently reported quarter was -$89.92M and diluted EPS was -$1.02.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BEAM since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BEAM analysts setting a high price target of $105.00 and a low target of $37.00, the average target price over the next 12 months is $67.93. Based on these targets, BEAM could surge 214.56% to reach the target high and rise by 10.84% to reach the target low. Reaching the average price target will result in a growth of 103.51% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded BEAM stock several times over the past three months with 9 Buys and 11 Sells. In these transactions, 156,766 shares were bought while 38,157 shares were sold. The number of buy transactions has increased to 25 while that of sell transactions has risen to 47 over the past year. The total number of shares bought during that period was 1,228,358 while 1,737,016 shares were sold.